Published in Proceedings of the National Academy of Sciences · View the paper (DOI)
A novel peptide has been developed to selectively detect and neutralize an early molecular trigger of Alzheimer's disease. The technology allows for the detection of the disease at all stages, including presymptomatic cases, with high sensitivity and specificity.
Coverage from 2 institutions